Skip to the answer

Ivabradine

Ivabradine is a heart-rate-lowering medicine used to treat heart failure: it reduces the risk of hospitalization for worsening heart failure in adults, and Corlanor is also approved for children with heart failure due to dilated cardiomyopathy.

Brand name Corlanor
Drug classes Hyperpolarization-activated Cyclic Nucleotide-gated Channel Antagonists
Rx Forms 2
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 12 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

Ivabradine at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Ivabradine (Corlanor) slows the heart's natural pacemaker without weakening its squeeze, lowering the risk of hospital stays for worsening heart failure. It is a specialist add-on for adults with a weak pumping heart (reduced ejection fraction) whose resting rate stays high despite a beta-blocker, and it is available generically after more than a decade on the market. Most people tolerate it well, and the side effect they notice is brief flashes or brightness in their vision (phosphenes), usually with sudden light changes and easing over time. Promptly report signs of a heart rate running too slow (dizziness, fainting, unusual tiredness), or a fluttering, irregular heartbeat, since that rhythm problem (atrial fibrillation) may mean stopping it.

Clinical pearls

  • Take it with food, and expect a heart rate check about two weeks in, when the dose may be adjusted.
  • Avoid grapefruit juice, diltiazem and verapamil, and never combine it with clarithromycin or itraconazole, which all raise its levels.
  • It may harm an unborn baby, so use effective contraception, and call your prescriber right away if you become pregnant.
  • Only Corlanor, which also comes as an oral solution, is approved for children with dilated cardiomyopathy (an enlarged, weakened heart).
How we write & review this content — our editorial policy →
How you get itPrescription only
Comes asTablet, Oral solution
Earliest FDA record2013
Companies listing it with the FDA12
FDA label last updatedNov 10, 2025
FDA’s strongest warning (boxed)None on the label

Patient information guide A plain-language walkthrough of Ivabradine, written from its FDA label.

What Ivabradine is used for

▾

Ivabradine is used to treat heart failure in the following ways:

  • Corlanor, ivabradine tablets (film coated), and ivabradine tablets are used in adults with stable, symptomatic chronic heart failure and a reduced ejection fraction (35% or less) to reduce the risk of hospitalization for worsening heart failure.
  • This use is for people in sinus rhythm with a resting heart rate of 70 beats per minute or higher who take maximally tolerated beta-blockers or cannot take them.
  • Corlanor is also used to treat stable symptomatic heart failure due to dilated cardiomyopathy in children 6 months and older in sinus rhythm with an elevated heart rate.

How Ivabradine works

▾

Ivabradine blocks the HCN channel that controls the heart's pacemaker current, which sets the heart rate. Its effects are strongest in the sinoatrial (SA) node, the heart's natural pacemaker. This lowers the heart rate without weakening the heart's pumping strength.

It can also affect a similar current in the retina, which may cause brief flashes of brightness in vision.

Ivabradine dosage

▾

Ivabradine is taken by mouth twice a day with food. Your prescriber checks your heart rate after about two weeks and adjusts the dose to reach a target rate. Dosing is guided by heart rate and how well you tolerate it.

  • Adults take tablets. Corlanor oral solution can be used if you cannot swallow tablets.
  • Children under 40 kg take Corlanor oral solution, dosed by weight. Children 40 kg or more take Corlanor tablets.
  • If a child's Corlanor dose is missed or spit out, do not give an extra dose. Give the next dose at the usual time.

Follow your prescriber's directions and the label.

Dosing details from the FDA-approved label

From the Ivabradine prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Adults
    • Starting dose 5 mg twice daily with food
    • After two weeks adjust dose to achieve a resting heart rate between 50 and 60 beats per minute (bpm)
    • Thereafter adjust as needed based on resting heart rate and tolerability
    • Maximum: 7.5 mg twice daily
    • Adults unable to swallow tablets can use oral solution
  • Adults with a history of conduction defects or other patients in whom bradycardia could lead to hemodynamic compromise (vulnerable adults)
    • Initiate therapy at 2.5 mg twice daily before increasing the dose based on heart rate
    • Maximum: 7.5 mg twice daily
    • Take with food
  • Adults: dose adjustment by heart rate > 60 bpm
    • Increase dose by 2.5 mg (given twice daily)
    • Maximum: 7.5 mg twice daily
  • Adults: dose adjustment by heart rate 50-60 bpm
    • Maintain dose
  • Adults: heart rate < 50 bpm or signs and symptoms of bradycardia
    • Decrease dose by 2.5 mg (given twice daily)
    • If current dose is 2.5 mg twice daily, discontinue therapy
  • Pediatric patients 6 months of age and older weighing less than 40 kg (oral solution)
    • Starting dose 0.05 mg/kg twice daily with food
    • Assess at two-week intervals and adjust dose by 0.05 mg/kg to target a heart rate reduction of at least 20%, based on tolerability
    • If bradycardia develops, reduce to previous titration step, and consider 0.02 mg/kg twice daily if it develops at the initial dosage
    • Maximum: 0.2 mg/kg twice daily (6 months to less than 1 year old) or 0.3 mg/kg twice daily (1 year old and older), up to a total of 7.5 mg twice daily
    • With food; if a dose is missed or spit out, do not give another dose, give next dose at usual time
  • Pediatric patients weighing 40 kg and greater (tablets)
    • Starting dose 2.5 mg twice daily with food
    • Assess at two-week intervals and adjust dose by 2.5 mg to target a heart rate reduction of at least 20%, based on tolerability
    • Maximum: 7.5 mg twice daily
    • Patients unable to swallow tablets can use oral solution
Read the label’s full dosing text

2. DOSAGE AND ADMINIST R ATION Adult and pediatric patients greater than 40 kg Starting dose is 2.5 (pediatrics and vulnerable adults) or 5 mg twice daily with food. After 2 weeks of treatment, adjust dose based on heart rate. The maximum dose is 7.5 mg twice daily. ( 2.1 ) Pediatric patients less than 40 kg Starting dose is 0.05 mg/kg twice daily with food. Adjust dose at two-week intervals by 0.05 mg/kg based on heart rate. Maximum dose is 0.2 mg/kg (patients 6 months to less than 1 year old) or 0.3 mg/kg (patients 1 year old and older), up to a total of 7.5 mg twice daily. 2.1 Adults The recommended starting dose of Corlanor is 5 mg twice daily with food. Assess patient after two weeks and adjust dose to achieve a resting heart rate between 50 and 60 beats per minute (bpm) as shown in Table 1. Thereafter, adjust dose as needed based on resting heart rate and tolerability. The maximum dose is 7.5 mg twice daily. In adult patients unable to swallow tablets, Corlanor oral solution can be used [see Clinical Pharmacology ( 12.3 )]. In patients with a history of conduction defects or other patients in whom bradycardia could lead to hemodynamic compromise, initiate therapy at 2.5 mg twice daily before increasing the dose based on heart rate [see Warnings and Precautions ( 5.3 )]. Table 1. Dose Adjustment for Adults Heart Rate Dose Adjustment > 60 bpm Increase dose by 2.5 mg (given twice daily) up to a maximum dose of 7.5 mg twice daily 50-60 bpm Maintain dose < 50 bpm or signs and symptoms of bradycardia Decrease dose by 2.5 mg (given twice daily); if current dose is 2.5 mg twice daily, discontinue therapy* * [ see Warnings and Precautions ( 5.3 )] 2.2 Pediatric Patients Recommended Dosage Pediatric Patients 6 Months of Age and Older Weighing Less than 40 kg (Oral Solution) The recommended starting dose of Corlanor oral solution in pediatric patients 6 months of age and older and weighing less than 40 kg is 0.05 mg/kg twice daily with food. Assess patient at two-week intervals and adjust dose by 0.05 mg/kg to target a heart rate (HR) reduction of at least 20%, based on tolerability. The maximum dose is 0.2 mg/kg twice daily for patients 6 months to less than 1 year old, and 0.3 mg/kg twice daily for patients 1 year old and older, up to a total of 7.5 mg twice daily.

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Ivabradine side effects

▾

Common side effects include:

Common side effects

  • Slow heart rate (bradycardia)
  • High blood pressure
  • Atrial fibrillation (irregular heartbeat)
  • Flashes or brightness in the vision (phosphenes)

When to get medical help

  • Call your doctor if you feel dizzy, faint, unusually tired, or short of breath, or if your heartbeat feels very slow. These can be signs of a slow heart rate.
  • Call your doctor if you notice a fast, fluttering, or irregular heartbeat. Atrial fibrillation may mean the medicine needs to be stopped.
  • Get urgent help for fainting, a racing or chaotic heartbeat, or swelling of the face, lips, or tongue.
  • Tell your doctor about vision changes such as double vision or visual impairment.
  • Call your doctor right away if you become pregnant while taking it.

Seek help for fainting, a very slow or irregular heartbeat, or swelling of the face, lips, or tongue. Reports after approval also include low blood pressure, dangerous heart rhythms, rash, vertigo, and double vision.

Ivabradine warnings and precautions

▾
  • Slow heart rate and heart block: These can occur, and risk is higher with conduction problems or other heart-slowing drugs.
  • Atrial fibrillation: Ivabradine raises the risk, so heart rhythm should be monitored and the drug stopped if it develops.
  • Pregnancy: It may harm an unborn baby based on animal studies. Effective contraception is advised.
  • It is not recommended with second-degree AV block unless a pacemaker is present.

Ivabradine interactions

▾

Ivabradine is broken down by an enzyme called CYP3A4, so many interactions involve that pathway.

  • Strong CYP3A4 inhibitors (itraconazole, clarithromycin, telithromycin, nelfinavir, nefazodone): must not be used, because they raise ivabradine levels and can worsen slow heart rate.
  • Diltiazem, verapamil, and grapefruit juice: avoid, since they raise ivabradine levels.
  • St. John's wort, rifampicin, barbiturates, phenytoin: avoid, since they lower ivabradine levels.
  • Digoxin, amiodarone, beta-blockers: add to heart-slowing effects, so heart rate is monitored.

Interactions listed in the FDA-approved label

From the Ivabradine prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Strong CYP3A4 inhibitors (e.g., azole antifungals such as itraconazole, macrolide antibiotics such as clarithromycin and telithromycin, HIV protease inhibitors such as nelfinavir, nefazodone): Increase ivabradine plasma concentrations, which may exacerbate bradycardia and conduction disturbances. Concomitant use is contraindicated.
  • Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, grapefruit juice): Increase ivabradine plasma concentrations, which may exacerbate bradycardia and conduction disturbances. Avoid concomitant use.
  • CYP3A4 inducers (e.g., St. John's wort, rifampicin, barbiturates, phenytoin): Decrease ivabradine plasma concentrations. Avoid concomitant use.
  • Negative chronotropes (e.g., digoxin, amiodarone, beta-blockers): The risk of bradycardia increases with concomitant administration of drugs that slow heart rate. Monitor heart rate.
  • Demand pacemakers set to a rate ≥ 60 beats per minute: Patients cannot achieve a target heart rate < 60 beats per minute; such patients were excluded from clinical trials. Use of ivabradine is not recommended.
Read the label’s full interactions text

7 DRUG INTERACTIONS Avoid CYP3A4 inhibitors or inducers. ( 7.1 ) Negative chronotropes increase risk of bradycardia; monitor heart rate. ( 7.2 ) 7.1 Cytochrome P450-Based Interactions Ivabradine is primarily metabolized by CYP3A4. Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations and use of CYP3A4 inducers decreases them. Increased plasma concentrations may exacerbate bradycardia and conduction disturbances. The concomitant use of strong CYP3A4 inhibitors is contraindicated [see Contraindications (4) and Clinical Pharmacology (12.3) ]. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g.,itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g.nelfinavir), and nefazodone. Avoid concomitant use of moderate CYP3A4 inhibitors when using ivabradine tablets. Examples of moderate CYP3A4 inhibitors include diltiazem, verapamil, and grapefruit juice [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3) ]. Avoid concomitant use of CYP3A4 inducers when using ivabradine tablets. Examples of CYP3A4 inducers include St. John's wort, rifampicin, barbiturates, and phenytoin [see Clinical Pharmacology (12.3) ]. 7.2 Negative Chronotropes Most patients receiving ivabradine tablets will also be treated with a beta-blocker. The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). Monitor heart rate in patients taking ivabradine tablets with other negative chronotropes. 7.3 Pacemakers in Adults Ivabradine tablets dosing is based on heart rate reduction, targeting a heart rate of 50 to 60 beats per minute in adults [see Dosage and Administration (2.1) ]. Patients with demand pacemakers set to a rate ≥ 60 beats per minute cannot achieve a target heart rate < 60 beats per minute, and these patients were excluded from clinical trials [see Clinical Studies (14.1) ].

Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿138 supplements and herbs with documented Ivabradine interactions, ranked by severity Check Ivabradine against a supplement or herb →

Before taking Ivabradine

▾
  • Do not use with acute decompensated heart failure, clinically significant low blood pressure, or clinically significant slow heart rate.
  • Do not use with sick sinus syndrome, sinoatrial block, or third-degree AV block unless a working pacemaker is present.
  • Do not use with severe liver impairment, pacemaker dependence, or strong CYP3A4 inhibitors.
  • Pregnancy: possible fetal harm. Use effective contraception.
  • Breastfeeding is not recommended.
  • Children: established for ages 6 months to under 18 years. Not established under 6 months.
  • Older adults: limited data in people 75 and older.
  • Mild to moderate liver impairment or kidney impairment (creatinine clearance 15 to 60 mL/min) does not require a dose change.

Ivabradine overdose

▾

Too much ivabradine can cause severe and prolonged slow heart rate. If the heart rate is slow and blood flow is poor, temporary pacing of the heart may be needed. Supportive care may include IV fluids, atropine, and IV medicines such as isoproterenol.

What Ivabradine does in the body

▾

Ivabradine lowers heart rate in a dose-related way, with larger effects in people with higher starting rates. At recommended doses, the drop is about 10 beats per minute at rest and during exercise. It does not reduce the heart's contractile strength. It can lengthen certain conduction intervals on an ECG and increases the uncorrected QT interval as the heart slows, without lengthening the rate-corrected QT.

How your body processes Ivabradine

▾

Ivabradine reaches peak blood levels in about 1 hour when fasting. About 40% of an oral dose is absorbed into the blood. Food delays absorption by about an hour and raises exposure by 20% to 40%, which is why it is taken with food. It is broken down mainly in the liver and gut by CYP3A4, and its active metabolite is similar in strength. Its effective half-life is about 6 hours, and the metabolites leave through urine and feces.

How to store Ivabradine

▾

Tablets : Corlanor (ivabradine) 5 mg tablets are formulated as salmon-colored, oval-shaped, film-coated tablets functionally scored on both edges, marked with “5” on one face and bisected on the other face.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

138

Supplements & herbs that interact with Ivabradine

138 supplements and herbal products have documented interactions with Ivabradine in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 3
  • Moderate · 94
  • Minor · 41
ACTIVATED CHARCOAL Major GRAPEFRUIT Major ST. JOHN'S WORT Major ACACIA RIGIDULA Moderate ADRAFINIL Moderate AFRICAN WILD POTATO Moderate AMERICAN ELDER Moderate ASTAXANTHIN Moderate +130 more
Every supplement checked against Ivabradine — ranked by severity The full interaction hub: 3 major · 94 moderate · 41 minor · every one linked to its full report. Check Ivabradine against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Ivabradine: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Ivabradine — the kind of thing our pharmacy team would talk through with you at the counter.

What is ivabradine for?

▾
It treats heart failure. In adults, it lowers the risk of being hospitalized when heart failure worsens, if your heart rate stays high despite beta-blockers or you can't take them. Corlanor is also approved for certain children with heart failure from dilated cardiomyopathy.

How should I take it?

▾
Take it by mouth twice a day with food. Your prescriber will check your heart rate after about two weeks and may adjust the dose. Follow their directions and your label. If you can't swallow tablets, Corlanor oral solution may be an option.

What side effects should I expect?

▾
The most common are a slower heart rate, higher blood pressure, atrial fibrillation, and flashes of brightness in your vision. The visual flashes usually start in the first couple of months and are mostly mild. Call your doctor if you feel faint, very tired, or notice an irregular heartbeat.

Can I take it with other medicines or grapefruit juice?

▾
Be careful. Some antifungals, antibiotics like clarithromycin, and HIV medicines must not be combined with it. Avoid grapefruit juice, diltiazem, verapamil, and St. John's wort. Always check with me before starting anything new.

Is it safe in pregnancy?

▾
It may harm an unborn baby, based on animal studies. If you could become pregnant, use effective contraception and tell your doctor right away if you become pregnant. Breastfeeding is not recommended.

Is Ivabradine available over the counter?

▾
No. Ivabradine is a prescription medicine: every Ivabradine product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Ivabradine first available?

▾
The earliest FDA record we hold for Ivabradine is from 2013: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Ivabradine was first used.

Who makes Ivabradine?

▾
12 companies currently list Ivabradine products in the FDA's NDC Directory, including Amgen Inc, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Ivabradine on HelloPharmacist

📊Ivabradine supplement interactions138 checked — ranked by severity 🌿Drug & Supplement CheckerIvabradine vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Ivabradine NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Ivabradine Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Ivabradine forms and strengths (how it comes)

Ivabradine is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Tablet

By mouth
Brands Corlanor
How this form is used
What it may be used for
  • Corlanor and ivabradine tablets are used in adults with stable, symptomatic chronic heart failure to reduce the risk of hospitalization for worsening heart failure.
  • Corlanor tablets are also used in children weighing 40 kg or more with heart failure due to dilated cardiomyopathy.
Important instructions
  • Corlanor and ivabradine tablets are taken twice daily with food.
  • Corlanor and ivabradine tablet doses are adjusted by your prescriber based on heart rate after about two weeks.
  • Corlanor and ivabradine tablets may be started at a lower dose in people at risk of problems from a slow heart rate.
Available strengths 2 strengths
5 mg 7.5 mg
31 FDA-listed product records ⓘ

Oral solution

By mouth
Brands Corlanor
How this form is used
What it may be used for
  • Corlanor oral solution is used for children 6 months and older weighing less than 40 kg with heart failure due to dilated cardiomyopathy.
  • Corlanor oral solution can be used in adults who cannot swallow tablets.
Important instructions
  • Corlanor oral solution is given twice daily with food.
  • If a Corlanor dose is missed or spit out, do not give another dose to make up for it. Give the next dose at the usual time.
  • Corlanor oral solution dosing in children is based on weight and adjusted by heart rate.
Available strengths 1 strength
5 mg/5 mL
3 FDA-listed product records ⓘ

Ivabradine on the U.S. market: products, makers and brands

How Ivabradine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

12 companies list 24 Ivabradine product records with the FDA, mostly as tablet, oral solution; the earliest marketing or approval year on record is 2013. Brand names on the directory include Corlanor; the rest are generics.

2
Dose forms ⓘ
12
Labelers (makers, repackagers, distributors)
2
Brand names
24
FDA-listed product records ⓘ
2013
Earliest FDA record ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (6) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Amgen Inc13%
Alembic Pharmaceuticals Inc.8%
Alembic Pharmaceuticals Limited8%
Bionpharma Inc.8%
Camber Pharmaceuticals, Inc.8%
Golden State Medical Supply, Inc.8%
Other makers46%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How widely Ivabradine is used (Medicaid data)

A general measure of how commonly Ivabradine is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Ivabradine is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

42,299
Medicaid prescriptions filled (Q1–Q4 2025)
$12M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Ivabradine prescribed? Of the 1,601 medications we measure, Ivabradine ranks #667 by Medicaid prescriptions — more than 58% of them.

Where Ivabradine ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #667 of 1,601
#662 Albendazole 43,095 Rx #663 Dapsone 42,610 Rx #664 Tezepelumab Injection 42,607 Rx #665 Dornase Alfa 42,474 Rx #666 Atenolol / Chlorthalid... 42,330 Rx #667 Ivabradine 42,299 Rx #668 Prucalopride 42,108 Rx #669 Gadoterate Meglumine 42,002 Rx #670 Linezolid 41,650 Rx #671 Trospium 41,279 Rx #672 Tofacitinib 41,140 Rx

Utilization by Ivabradine product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 5 mg oral tablet is the most-dispensed Ivabradine product — about 81% of these Medicaid prescriptions.

ivabradine 5 MG Oral Tablet Most dispensed

34,456 Medicaid prescriptions (Q1–Q4 2025) 81% of Ivabradine prescriptions shown $9.4M gross reimbursement (before rebates) ≈ $273 per prescription (gross)

Summed across the 6 of 24 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1649485

ivabradine 7.5 MG Oral Tablet

7,649 Medicaid prescriptions (Q1–Q4 2025) 18% of Ivabradine prescriptions shown $2.5M gross reimbursement (before rebates) ≈ $322 per prescription (gross)

Summed across the 6 of 19 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1649493

ivabradine 1 MG/ML Oral Solution

194 Medicaid prescriptions (Q1–Q4 2025) <1% of Ivabradine prescriptions shown $115,805 gross reimbursement (before rebates) ≈ $597 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2168592

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Ivabradine, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 13 of 45 listed Ivabradine NDCs with Medicaid activity.

Compare Ivabradine products

A representative set of FDA-listed product records for Ivabradine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 24 of 24 products — FDA National Drug Code Directory. See every product, package size and price: browse all 24 Ivabradine NDCs →

Ivabradine recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list one Ivabradine recall since July 2021, covering 2 product listings. It is still ongoing. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.

Ongoing Class II Jun 4, 2026 · Amgen, Inc.
Presence of Foreign Substance.
  • Corlanor (ivabradine) tablets, 7.5mg, 60-count bottles, Rx Only, Amgen Inc., Thousand Oaks, CA 92130 Made In Italy. NDC 55513-810-60 Lots: Lot #: 1138203, 1142065, Exp. Date 07/31/2026; 1145151, 1145152, 1145153, Exp. Date 2/28/2027; 1148908, 1148909, Exp. Date 05/31/2027; 1162845, 1162846, Exp. Date 11/30/2027; 1166471, 1166472, 1166473, Exp. Date 05/31/2028; 1170615, Exp. D… FDA record D-0615-2026 →
  • Corlanor (ivabradine) tablets, 5 mg, packaged in a) 14 tablets bottles (NDC 55513-800-99), and b) 60 tablet bottles (NDC 55513-800-60), Rx Only, Amgen Inc., Thousand Oaks, CA 92130 Made In Italy. Lots: a) Lot # 1138901, Exp. Date 08/31/2026; 1149846, Exp. Date 04/30/2027 b) Lot #1138201, 1138202, 08/31/2026, 1138900, 1141143, Exp. Date 08/31/2026; 1140280, 1140281, 1142063, Exp. Date 10/31/2026; 1142062, 1142942, 1142943, Exp. Date 11/30… FDA record D-0612-2026 →

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Ivabradine RxCUI 1649480 2 dose forms · 3 strengths
  1. Dose form (SCDF) Oral Solution RxCUI 2168591 In current FDA listings
    Clinical drug / strength (SCD) 1 MG/ML RxCUI 2168592
  2. Dose form (SCDF) Oral Tablet RxCUI 1649484 In current FDA listings
    Clinical drug / strength (SCD) 5 MG RxCUI 1649485 7.5 MG RxCUI 1649493

Look up RxCUI 1649480 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

💵 What Ivabradine costs pharmacies (NADAC benchmark)

The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.

FormStrengthPharmacy acquisition benchmark
Tablet, Film Coated · Oral 5 mg $0.761 per tablet NDC details & price history
Tablet, Film Coated · Oral 7.5 mg $0.640 per tablet NDC details & price history
Tablet · Oral 5 mg $0.761 per tablet NDC details & price history
Tablet · Oral 7.5 mg $0.640 per tablet NDC details & price history
Why show this? Your out-of-pocket cost depends on insurance, pharmacy markup, and discounts — but the acquisition benchmark tells you whether the medication itself is inexpensive or costly, which strengths cost more per dose, and whether a cash-price quote is in a reasonable range. Each row links to the NDC-level record with its full price history.

Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.

Ivabradine brand names

Ivabradine is sold under one brand name in the FDA directory — Corlanor. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Corlanor

Who makes Ivabradine: manufacturers and labelers

12 companies list Ivabradine products with the FDA. By number of product records, the largest are Amgen Inc, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Amgen Inc 3 Alembic Pharmaceuticals Inc. 2 Alembic Pharmaceuticals Limited 2 Bionpharma Inc. 2 Camber Pharmaceuticals, Inc. 2 Golden State Medical Supply, Inc. 2 Ingenus Pharmaceuticals, LLC 2 Northstar Rx LLC 2 Novadoz Pharmaceuticals LLC 2 Zydus Lifesciences Limited 2 Zydus Pharmaceuticals USA Inc. 2 American Health Packaging 1

Ivabradine drug class (RxNorm)

Ivabradine belongs to the Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker class.

Pharmacologic class Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker
Drug family (ATC) Other cardiac preparations
How it works Hyperpolarization-activated Cyclic Nucleotide-gated Channel Antagonists

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Ivabradine page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Nov 10, 2025
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Ivabradine.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Ivabradine after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
12
Finished products in the current FDA directory
24
Companies listing them (makers, repackagers, distributors)
12
FDA labeler codes behind them ⓘ
12
Linked representative label ⓘ
Amgen Inc
Linked label effective
Nov 10, 2025
Composite sections available
25
Linked SPL Set ID
92018a65-38f6-45f7-91d4-a34921b81d0d
Linked SPL Document ID
8ab000cd-0258-489a-b1bb-4cc1ca359d6c
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Amgen Inc is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →